Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway

Jochen Klucken, Anne Maria Poehler, Darius Ebrahimi-Fakhari, Jacqueline Schneider, Silke Nuber, Edward Rockenstein, Ursula Schlötzer-Schrehardt, Bradley T. Hyman, Pamela J McLean, Eliezer Masliah, Juergen Winkler

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Synucleinopathies like Parkinson disease and dementia with Lewy bodies (DLB) are characterized by α-synuclein aggregates within neurons (Lewy bodies) and their processes (Lewy neurites). Whereas α-synuclein has been genetically linked to the disease process, the pathological relevance of α-synuclein aggregates is still debated. Impaired degradation is considered to result in aggregation of α-synuclein. In addition to the ubiquitin-proteasome degradation, the autophagy-lysosomal pathway (ALP) is involved in intracellular degradation processes for a-synuclein. Here, we asked if modulation of ALP affects α-synuclein aggregation and toxicity. We have identified an induction of the ALP markers LAMP-2A and LC3-II in human brain tissue from DLB patients, in a transgenic mouse model of synucleinopathy, and in a cell culture model for α-synuclein aggregation. ALP inhibition using bafilomycin A 1 (BafA1) significantly potentiates toxicity of aggregated α-synuclein species in transgenic mice and in cell culture. Surprisingly, increased toxicity is paralleled by reduced aggregation in both in vivo and in vitro models. The dichotomy of effects on aggregating and nonaggregating species of α-synuclein was specifically sensitive to BafA1 and could not be reproduced by other ALP inhibitors. The present study expands on the accumulating evidence regarding the function of ALP for α-synuclein degradation by isolating an aggregation specific, BafA1-sensitive, ALP-related pathway. Our data also suggest that protein aggregation may represent a detoxifying event rather than being causal for cellular toxicity.

Original languageEnglish (US)
Pages (from-to)754-766
Number of pages13
JournalAutophagy
Volume8
Issue number5
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Synucleins
alpha-Synuclein
Autophagy
Lewy Body Disease
Transgenic Mice
Cell Culture Techniques
bafilomycin A
Lewy Bodies
Neurites
Proteasome Endopeptidase Complex
Pathologic Processes
Ubiquitin
Parkinson Disease

Keywords

  • Alpha-synuclein
  • Dementia with lewy bodies (DLB)
  • Lewy body
  • Lysosomal degradation
  • Parkinson disease (PD)
  • Protein aggregation

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Klucken, J., Poehler, A. M., Ebrahimi-Fakhari, D., Schneider, J., Nuber, S., Rockenstein, E., ... Winkler, J. (2012). Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy, 8(5), 754-766. https://doi.org/10.4161/auto.19371

Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. / Klucken, Jochen; Poehler, Anne Maria; Ebrahimi-Fakhari, Darius; Schneider, Jacqueline; Nuber, Silke; Rockenstein, Edward; Schlötzer-Schrehardt, Ursula; Hyman, Bradley T.; McLean, Pamela J; Masliah, Eliezer; Winkler, Juergen.

In: Autophagy, Vol. 8, No. 5, 05.2012, p. 754-766.

Research output: Contribution to journalArticle

Klucken, J, Poehler, AM, Ebrahimi-Fakhari, D, Schneider, J, Nuber, S, Rockenstein, E, Schlötzer-Schrehardt, U, Hyman, BT, McLean, PJ, Masliah, E & Winkler, J 2012, 'Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway', Autophagy, vol. 8, no. 5, pp. 754-766. https://doi.org/10.4161/auto.19371
Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E et al. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy. 2012 May;8(5):754-766. https://doi.org/10.4161/auto.19371
Klucken, Jochen ; Poehler, Anne Maria ; Ebrahimi-Fakhari, Darius ; Schneider, Jacqueline ; Nuber, Silke ; Rockenstein, Edward ; Schlötzer-Schrehardt, Ursula ; Hyman, Bradley T. ; McLean, Pamela J ; Masliah, Eliezer ; Winkler, Juergen. / Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. In: Autophagy. 2012 ; Vol. 8, No. 5. pp. 754-766.
@article{1dfd252fe92f42e6a73936ce6f3daa8f,
title = "Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway",
abstract = "Synucleinopathies like Parkinson disease and dementia with Lewy bodies (DLB) are characterized by α-synuclein aggregates within neurons (Lewy bodies) and their processes (Lewy neurites). Whereas α-synuclein has been genetically linked to the disease process, the pathological relevance of α-synuclein aggregates is still debated. Impaired degradation is considered to result in aggregation of α-synuclein. In addition to the ubiquitin-proteasome degradation, the autophagy-lysosomal pathway (ALP) is involved in intracellular degradation processes for a-synuclein. Here, we asked if modulation of ALP affects α-synuclein aggregation and toxicity. We have identified an induction of the ALP markers LAMP-2A and LC3-II in human brain tissue from DLB patients, in a transgenic mouse model of synucleinopathy, and in a cell culture model for α-synuclein aggregation. ALP inhibition using bafilomycin A 1 (BafA1) significantly potentiates toxicity of aggregated α-synuclein species in transgenic mice and in cell culture. Surprisingly, increased toxicity is paralleled by reduced aggregation in both in vivo and in vitro models. The dichotomy of effects on aggregating and nonaggregating species of α-synuclein was specifically sensitive to BafA1 and could not be reproduced by other ALP inhibitors. The present study expands on the accumulating evidence regarding the function of ALP for α-synuclein degradation by isolating an aggregation specific, BafA1-sensitive, ALP-related pathway. Our data also suggest that protein aggregation may represent a detoxifying event rather than being causal for cellular toxicity.",
keywords = "Alpha-synuclein, Dementia with lewy bodies (DLB), Lewy body, Lysosomal degradation, Parkinson disease (PD), Protein aggregation",
author = "Jochen Klucken and Poehler, {Anne Maria} and Darius Ebrahimi-Fakhari and Jacqueline Schneider and Silke Nuber and Edward Rockenstein and Ursula Schl{\"o}tzer-Schrehardt and Hyman, {Bradley T.} and McLean, {Pamela J} and Eliezer Masliah and Juergen Winkler",
year = "2012",
month = "5",
doi = "10.4161/auto.19371",
language = "English (US)",
volume = "8",
pages = "754--766",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway

AU - Klucken, Jochen

AU - Poehler, Anne Maria

AU - Ebrahimi-Fakhari, Darius

AU - Schneider, Jacqueline

AU - Nuber, Silke

AU - Rockenstein, Edward

AU - Schlötzer-Schrehardt, Ursula

AU - Hyman, Bradley T.

AU - McLean, Pamela J

AU - Masliah, Eliezer

AU - Winkler, Juergen

PY - 2012/5

Y1 - 2012/5

N2 - Synucleinopathies like Parkinson disease and dementia with Lewy bodies (DLB) are characterized by α-synuclein aggregates within neurons (Lewy bodies) and their processes (Lewy neurites). Whereas α-synuclein has been genetically linked to the disease process, the pathological relevance of α-synuclein aggregates is still debated. Impaired degradation is considered to result in aggregation of α-synuclein. In addition to the ubiquitin-proteasome degradation, the autophagy-lysosomal pathway (ALP) is involved in intracellular degradation processes for a-synuclein. Here, we asked if modulation of ALP affects α-synuclein aggregation and toxicity. We have identified an induction of the ALP markers LAMP-2A and LC3-II in human brain tissue from DLB patients, in a transgenic mouse model of synucleinopathy, and in a cell culture model for α-synuclein aggregation. ALP inhibition using bafilomycin A 1 (BafA1) significantly potentiates toxicity of aggregated α-synuclein species in transgenic mice and in cell culture. Surprisingly, increased toxicity is paralleled by reduced aggregation in both in vivo and in vitro models. The dichotomy of effects on aggregating and nonaggregating species of α-synuclein was specifically sensitive to BafA1 and could not be reproduced by other ALP inhibitors. The present study expands on the accumulating evidence regarding the function of ALP for α-synuclein degradation by isolating an aggregation specific, BafA1-sensitive, ALP-related pathway. Our data also suggest that protein aggregation may represent a detoxifying event rather than being causal for cellular toxicity.

AB - Synucleinopathies like Parkinson disease and dementia with Lewy bodies (DLB) are characterized by α-synuclein aggregates within neurons (Lewy bodies) and their processes (Lewy neurites). Whereas α-synuclein has been genetically linked to the disease process, the pathological relevance of α-synuclein aggregates is still debated. Impaired degradation is considered to result in aggregation of α-synuclein. In addition to the ubiquitin-proteasome degradation, the autophagy-lysosomal pathway (ALP) is involved in intracellular degradation processes for a-synuclein. Here, we asked if modulation of ALP affects α-synuclein aggregation and toxicity. We have identified an induction of the ALP markers LAMP-2A and LC3-II in human brain tissue from DLB patients, in a transgenic mouse model of synucleinopathy, and in a cell culture model for α-synuclein aggregation. ALP inhibition using bafilomycin A 1 (BafA1) significantly potentiates toxicity of aggregated α-synuclein species in transgenic mice and in cell culture. Surprisingly, increased toxicity is paralleled by reduced aggregation in both in vivo and in vitro models. The dichotomy of effects on aggregating and nonaggregating species of α-synuclein was specifically sensitive to BafA1 and could not be reproduced by other ALP inhibitors. The present study expands on the accumulating evidence regarding the function of ALP for α-synuclein degradation by isolating an aggregation specific, BafA1-sensitive, ALP-related pathway. Our data also suggest that protein aggregation may represent a detoxifying event rather than being causal for cellular toxicity.

KW - Alpha-synuclein

KW - Dementia with lewy bodies (DLB)

KW - Lewy body

KW - Lysosomal degradation

KW - Parkinson disease (PD)

KW - Protein aggregation

UR - http://www.scopus.com/inward/record.url?scp=84862598619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862598619&partnerID=8YFLogxK

U2 - 10.4161/auto.19371

DO - 10.4161/auto.19371

M3 - Article

C2 - 22647715

AN - SCOPUS:84862598619

VL - 8

SP - 754

EP - 766

JO - Autophagy

JF - Autophagy

SN - 1554-8627

IS - 5

ER -